CareDx's CEO Sells 17K Shares

Published: Monday, June 22, 2026 at 1:58 am

CareDx CEO Sells Shares in Scheduled Transaction

John Hanna, President and CEO of CareDx, a company specializing in transplant diagnostics, has sold 17,683 shares of common stock for approximately $425,000. The transaction, which took place on June 15, was disclosed in a filing with the Securities and Exchange Commission.

This sale is part of a pre-arranged trading plan, known as a Rule 10b5-1 plan. These plans are designed to allow company insiders to sell shares without the appearance of trading on non-public information. The terms of the sale, including its timing, were established in advance. This is not an isolated event, as Mr. Hanna has completed four such transactions since April 1, indicating a consistent approach to managing his holdings.

Following this sale, Mr. Hanna directly holds 631,959 shares of CareDx stock.

CareDx is recognized for its innovation in transplant diagnostics, utilizing proprietary cell-free DNA and gene expression technologies. The company offers a range of molecular tests and digital solutions aimed at improving post-transplant monitoring and patient care. Its product portfolio includes tests for kidney, heart, and lung transplants, as well as gene expression profiling and HLA typing solutions. CareDx primarily generates revenue through the sale of its diagnostic tests, software platforms, and related services to transplant centers and laboratories.

While insider sales, especially those by a CEO, often attract investor attention due to the potential for privileged information, the use of a Rule 10b5-1 plan in this instance suggests the sales are part of a predetermined liquidity strategy. Other CareDx insiders have also recently disclosed sales under similar plans, which are not expected to raise concerns among investors.

Despite a recent gain of 37.5% in its stock price over the past year, CareDx's performance has lagged behind the broader market, as measured by the Russell 2000 index, which saw a 43% total return during the same period.

BNN's Perspective:

The sale of shares by CareDx's CEO, while a notable event, appears to be a routine part of a pre-established trading strategy. The utilization of a Rule 10b5-1 plan mitigates concerns about insider trading, suggesting the transaction is driven by personal financial planning rather than an indication of negative company outlook. Investors should consider this sale within the context of the company's ongoing operations and its performance relative to market benchmarks.

Tags: CareDx, CDNA, CEO, President, John Hanna, share sale, insider transaction, Rule 10b5-1, transplant diagnostics, molecular tests, SEC Form 4, stock performance, Russell 2000

Full Story